| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2102262 | Biology of Blood and Marrow Transplantation | 2015 | 5 Pages |
•One hundred twenty-six patients underwent autologous stem cell transplantation for primary refractory myeloma.•At 100 days, the complete response and partial response rates were 21% and 74%, respectively.•Median progression-free survival and overall survival were 18 and 51 months, respectively.•Autologous stem cell transplantation is effective for multiple myeloma refractory to modern induction therapies.
High-dose therapy and autologous stem cell transplantation (ASCT) have proven efficacy in patients with multiple myeloma responding well to induction therapy. For those who fail to achieve a stable partial response (PR), the effect of ASCT is unclear. We report on 126 patients identified from a national database, who underwent ASCT having achieved
